AMs recommend that pharmacists have access to palliative care data in Wales

AMs recommend that pharmacists have access to palliative care data in Wales

July 18 2018 Community pharmacists should be among those health professionals who are alerted to...

APTUK questions claims about pharmacy technicians’ desire to supervise medicines supplies

APTUK questions claims about pharmacy technicians’ desire to supervise medicines supplies

July 18 2018 The Association of Pharmacy Technicians UK is questioning a survey on pharmacy...

Community pharmacy briefing for MPs due this week

Community pharmacy briefing for MPs due this week

July 16 2018 Community pharmacy organisations are due to brief MPs at Westminster on Tuesday 17...

GPhC asks for views on publication and disclosure policy update in light of GDPR

GPhC asks for views on publication and disclosure policy update in light of GDPR

July 10 2018 The General Pharmaceutical Council is seeking views on how its publication and...

CMO concludes cannabis products should move out of Schedule 1 classification

CMO concludes cannabis products should move out of Schedule 1 classification

July 9 2018 The Chief Medical Officer has recommended rescheduling cannabis-based products as...

  • AMs recommend that pharmacists have access to palliative care data in Wales

    AMs recommend that pharmacists have access to palliative care data in Wales

    Wednesday, 18 July 2018 17:41
  • APTUK questions claims about pharmacy technicians’ desire to supervise medicines supplies

    APTUK questions claims about pharmacy technicians’ desire to supervise medicines supplies

    Wednesday, 18 July 2018 17:17
  • Community pharmacy briefing for MPs due this week

    Community pharmacy briefing for MPs due this week

    Monday, 16 July 2018 15:31
  • GPhC asks for views on publication and disclosure policy update in light of GDPR

    GPhC asks for views on publication and disclosure policy update in light of GDPR

    Tuesday, 10 July 2018 09:29
  • CMO concludes cannabis products should move out of Schedule 1 classification

    CMO concludes cannabis products should move out of Schedule 1 classification

    Monday, 09 July 2018 09:18

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a cannibis leaf imageJuly 9 2018

The Chief Medical Officer has recommended rescheduling cannabis-based products as evidence indicates they have the potential for medicinal use.

Schedule 1 of the Misuse of Drugs Regulations 2001 is for those compounds which “by definition have little or no therapeutic potential.” Recent publicity over medicinal uses for cannabis products has prompted the consideration for rescheduling the drug. 

The CMO, Professor Dame Sally Davies, has now made her recommendations following a review of the evidence for the therapeutic benefit of cannabis-based medicinal products. 

“The evidence that cannabis and some of its derivatives can be addictive and harmful has been known for some time and is not disputed by recent science, so I believe the reasons it is a controlled drug in the UK stand,” says her report.

“There is now however, conclusive evidence of the therapeutic benefit of cannabis based medicinal products for certain medical conditions and reasonable evidence of therapeutic benefit in several other medical conditions.” 

Having reviewed “robust” evidence, Prof Davies’s review says: “I believe that it would not make sense to move cannabis and its derivatives out of Schedule 1 whilst leaving synthetic cannabinoids, which the evidence suggests have potentially greater therapeutic benefit and less potential for harm, in Schedule 1. 

“I therefore recommend that the whole class of cannabis based medicinal products be moved out of Schedule 1.”

In publishing the review, the Department of Health and Social Care said: “This review forms part of a series of measures announced by the Home Secretary on 19 June 2018 looking at the scheduling of cannabis. Its conclusion signals the start of a second review, which will be led by the Advisory Council on the Misuse of Drugs (ACMD).

“The ACMD will not reassess the evidence issued by Professor Dame Sally Davies but will provide an assessment, based on the balance of harms and public health needs, of what (if anything) should be rescheduled.”

Links:
DHSC announcement    
CMO Review: ‘Cannabis Scheduling Review Part 1 The therapeutic and medicinal benefits of Cannabis based products – a review of recent evidence’. July 3 2018. 

Legal & Policy News

July 19 2018 The medicines regulator has issued a Drug Safety Update relating to suspected adverse drug reactions associated with medicines taken during pregnancy.
July 11 2018 New Medicines Service data indicates community pharmacists manage 19 out of 20 hypertensive patients without the need to refer a patient back to the GP. Analysis of 131,419 patient...